Enzo Biochem (ENZB) AI Stock Analysis

• Market Cap: $30.66M
• Dividend Yield: N/A
• Average Volume (3M): 56.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 125
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 52,402,805
• 10 Day Avg. Volume: 38,386
• 30 Day Avg. Volume: 56,133
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: $0.50 ▼(-15.25%Downside)

Enzo Biochem's overall stock score is driven largely by its financial performance challenges, including negative profit margins and cash flow issues. While technical indicators provide some optimism, the unfavorable valuation metrics further weigh down the score.

Enzo Biochem Business Overview & Revenue Model

Company Description

Enzo Biochem, Inc. (ENZB) is a life sciences and biotechnology company specializing in the development, manufacture, and sale of innovative products and technologies for research, diagnostics, and therapeutics. The company operates primarily through two segments: Enzo Clinical Labs and Enzo Life Sciences. Enzo Clinical Labs provides a full range of clinical laboratory and pathology services, while Enzo Life Sciences develops, manufactures, and markets reagents, assays, and systems used in medical research and drug development.

How the Company Makes Money

Enzo Biochem generates revenue primarily through its two operating segments. Enzo Clinical Labs earns money by providing diagnostic and clinical laboratory testing services to physicians, medical centers, and other healthcare providers. This includes routine blood tests, molecular diagnostics, and specialized testing services. Enzo Life Sciences generates revenue by selling a wide range of life sciences products, including reagents, assays, and kits to academic institutions, biopharmaceutical companies, and laboratories worldwide. The company also benefits from partnerships and licensing agreements that leverage its proprietary technologies and intellectual property, contributing to its earnings.

Enzo Biochem Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement		Total Revenue
	Gross Profit
	EBIT
	EBITDA
	Net Income Common Stockholders
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
	Total Assets
	Total Debt
	Net Debt
	Total Liabilities
	Stockholders Equity
Cash Flow		Free Cash Flow
	Operating Cash Flow
	Investing Cash Flow
	Financing Cash Flow

Enzo Biochem Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.59
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENZB, the sentiment is Positive. The current price of 0.59 is above the 20-day moving average (MA) of 0.59, above the 50-day MA of 0.49, and below the 200-day MA of 0.73, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 57.48 is Neutral, neither overbought nor oversold. The STOCH value of 42.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENZB.

Enzo Biochem Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TVRD	57 Neutral	$245.44M	―	-414.88%	―	-65.96%	40.80%
ENZB	54 Neutral	$30.66M	―	-12.94%	―	―	―
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
IGC	45 Neutral	$24.66M	―	-115.06%	―	1.64%	50.63%
ENLV	36 Underperform	$22.47M	―	-60.35%	―	―	53.95%
BCAB	35 Underperform	$27.02M	―	-246.21%	―	―	44.38%
NRSN	30 Underperform	$59.73M	―	-2880.11%	―	―	31.09%